Olmesartan

Olmesartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for Benicar tablets (olmesartan medoxomil), lists one use: treating high blood pressure in adults and in children six years of age and older. Benicar is the brand name on the label read.

Also called Benicar · Olmesartan medoxomil

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 321064; UNII 6M97XTV3HD. The label names the substance as olmesartan medoxomil, a prodrug that the label says is hydrolyzed to olmesartan, so UNII 6M97XTV3HD is the UNII of the medoxomil ester and is a broad match. MeSH descriptor D000068557 is Olmesartan Medoxomil, also a broad match. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Cosette Pharmaceuticals, Inc. label for Benicar (olmesartan medoxomil) tablets, application NDA021286, effective 2025-09-23 in openFDA; Drugs@FDA lists the application's sponsor as COSETTE. The older Benicar label with set id 5b6f8a18 (dated 2023-07-12), generic olmesartan labels and the Benicar HCT combination labels were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 13 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
13
Phase 3 or 4
9
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 23014
Phase 35016
Phase 41113
All phases91313

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 3 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII 6M97XTV3HD
  • MeSH read 2026-11-09 D000068557

Claims and evidence

Context Adults for whom the US label of olmesartan (Benicar) lists an indication: hypertension

Recipient
Adult
Population
Adult patients described in the indications section of the label. The hypertension sentence also names children six years of age and older, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the passage read states
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Adult patients with hypertension
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children six years of age and older, recorded separately).

    Applies to Adult Adults for whom the US label of olmesartan (Benicar) lists an indication: hypertension

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-09-23
      Source state
      Current
      Version fingerprint
      380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250923.
      Retrieved
      Source effective date
      2025-09-23
      Source state
      Current
      Version fingerprint
      380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA Drugs@FDA record for application NDA021286 (BENICAR, sponsor COSETTE): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application NDA021286, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application NDA021286, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ada3a2c27b76f10d908badc757070fe0fffe28b6cfbafef3ceaac5819a15264f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

Context Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older

Recipient
Child
Population
Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Label wording: children six years of age and older
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Children with hypertension (children six years of age and older)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in children six years of age and older, to lower blood pressure.

    Applies to Child Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2025-09-23
      Source state
      Current
      Version fingerprint
      380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250923.
      Retrieved
      Source effective date
      2025-09-23
      Source state
      Current
      Version fingerprint
      380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in children six years of age and older, to lower blood pressure.

    Applies to Child Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older

    Population, setting and follow-up
    • Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Label wording: children six years of age and older
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2025-09-23
      Source state
      Current
      Version fingerprint
      380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250923.
      Retrieved
      Source effective date
      2025-09-23
      Source state
      Current
      Version fingerprint
      380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

AZOR

No label from the application holder was found in the openFDA label dataset for application NDA022100. This page does not show another labeler's label in its place.

BENICAR

No label from the application holder was found in the openFDA label dataset for application NDA021286. This page does not show another labeler's label in its place.

BENICAR HCT

No label from the application holder was found in the openFDA label dataset for application NDA021532. This page does not show another labeler's label in its place.

TRIBENZOR

No label from the application holder was found in the openFDA label dataset for application NDA200175. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA021286 BENICAR
  2. Approval NDA021532 BENICAR HCT
  3. Approval NDA022100 AZOR
  4. Supplemental approval NDA022100 AZOR
  5. Supplemental approval NDA021286 BENICAR
  6. Approval NDA200175 TRIBENZOR

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 4

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA021286

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA021532

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA022100

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA200175

Registry trials 13

Record details

Record id
cardio:olmesartan
Content hash
d53eb236c363311721a4bcbed7ea56a28c82350486591a9a1fd5032238339f02